Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPX9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,729
Award facts
- Contract value 100% obligated
- $83,728.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $83,728.70 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The award was issued on December 17, 2025, with an ultimate completion date of January 9, 2026, and carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.99 billion acquisition strategy designed to provide comprehensive pharmaceutical supplies to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has demonstrated substantial federal contracting capability across multiple therapeutic categories including oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The vendor's established performance on numerous delivery orders from the DLA positions it as a critical supplier within the federal military medical system. The PPV-G GEN V contract structure enables the DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, with the base period extending through December 31, 2036.
Quick answers
Who was awarded contract SPE2DR26FQPX9?
SPE2DR26FQPX9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FQPX9 worth?
The government has obligated $83,729 on SPE2DR26FQPX9.
Is contract SPE2DR26FQPX9 an order under another contract?
Yes. SPE2DR26FQPX9 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPX9 competed?
The extent of competition for SPE2DR26FQPX9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award